Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Pharmaceutical Sciences Research Center, Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Mol Biol Rep. 2023 Nov;50(11):8827-8837. doi: 10.1007/s11033-023-08754-1. Epub 2023 Sep 2.
RNA (ribonucleic acid) antisense is developing as a possible treatment option. As an RNA, miR-34a is involved in P53 function and cancer cell apoptosis. Although the therapeutic applications of miRNAs have several limitations, such as structural instability and susceptibility to nucleases. To resolve these issues, this study aims to apply exosomes as a delivery vehicle for miR-34a.
This study aims to create a cell factory to generate miR34a-enriched exosomes. The produced nanoparticles act as a delivery system and improve the structural stability of miR34a.
First exosome specific sequences were inserted into miR34a. The resulting miR34a oligonucleotide was transduced HEK293T cells genome with a lentiviral system. In the structure of miR34a oligonucleotide, six nucleotides were substituted to increase its packaging rate into exosomes. To maintain the secondary structure, stability, and expression of the miRNA gene, changes to the miR34a oligonucleotide were made using PCR (polymerase chain reaction) Extension. The forward-34a (5-TGGGGAGAGGCAGGACAGG-3) and Reverse-34a primers (5-TCCGAAGTCCTGGCGTCTCC-3) were used for amplification of the miR34a gene from DNA.
The results confirmed that the changes in miR34a oligonucleotide do not affect its secondary structure. The energy level of the manipulated miR34a oligonucleotide was kept the same compared to the original one. Moreover, the loading of miR34a to the exosomes was increased.
Our findings revealed that normal HEK293T did not express miR34a. However, lentiviral transduced miR34a oligonucleotide induced the loading of miR34a into the exosome. Moreover, replacing six nucleic acids in the 3' end of miR34a increased the loading of miR34a to exosome.
RNA(核糖核酸)反义技术正在成为一种可能的治疗选择。miR-34a 作为一种 RNA,参与 P53 功能和癌细胞凋亡。尽管 miRNA 的治疗应用存在一些局限性,如结构不稳定和易受核酸酶影响。为了解决这些问题,本研究旨在应用外泌体作为 miR-34a 的递送载体。
本研究旨在创建一个细胞工厂来产生富含 miR34a 的外泌体。所产生的纳米颗粒作为递送系统,可提高 miR34a 的结构稳定性。
首先将外泌体特异性序列插入 miR34a 中。通过慢病毒系统将 resulting miR34a 寡核苷酸转导至 HEK293T 细胞基因组中。在 miR34a 寡核苷酸的结构中,替换了六个核苷酸以增加其包装到外泌体中的比率。为了保持 miRNA 基因的二级结构、稳定性和表达,使用 PCR(聚合酶链反应)延伸对 miR34a 寡核苷酸进行了修饰。正向 34a(5-TGGGGAGAGGCAGGACAGG-3)和反向 34a 引物(5-TCCGAAGTCCTGGCGTCTCC-3)用于从 DNA 扩增 miR34a 基因。
结果证实,miR34a 寡核苷酸的变化不影响其二级结构。与原始 miR34a 相比,操纵的 miR34a 寡核苷酸的能量水平保持不变。此外,miR34a 加载到外泌体中的量增加。
我们的研究结果表明,正常的 HEK293T 细胞不表达 miR34a。然而,慢病毒转导的 miR34a 寡核苷酸诱导 miR34a 加载到外泌体中。此外,在 miR34a 的 3' 端替换六个核酸增加了 miR34a 加载到外泌体的量。